BioSpace News Archive

via NewMediaWire – HearAtLast Holdings Inc., a Nevada Corporation, is pleased to announce the long anticipated integration of Crystal Clear Audio, Inc., that HearAtlast acquired in 2019.

Molecular diagnostics company Genetic Technologies Ltd (ASX: GTG; NASDAQ: GENE, the ‘Company’), announced today that they have entered into a three-year partnership agreement with mental health company, Taliaz, for the distribution rights of their PREDICTIX products in Australia, New Zealand and the USA (“Agreement”).

Medicure Inc. (" Medicure " or the " Company ") (TSXV: MPH) (OTC:MCUJF), a cardiovascular pharmaceutical company, today announces that it has retained the services of Renmark Financial Communications Inc. (" Renmark ") to condu

Financing led by Blumberg Capital supports Segmed’s mission to aggregate medical data for research in support of improving healthcare around the world

Qualigen Therapeutics, Inc. (Nasdaq: QLGN) announces that it has completed the recertification of its supply of AS1411, and has begun final formulation and filling for use in the Company’s proposed Phase 2a efficacy trials of AS1411 for the treatment of patients with COVID-19.

Taiho Oncology, Inc. and Astex Pharmaceuticals, Inc. today announced that data for oral decitabine and cedazuridine (INQOVI® [decitabine and cedazuridine] 35mg/100mg tablets) in intermediate and high-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) will be presented during the 62nd Annual American Society of Hematology Meeting and Exposition (ASH 2020),

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has granted a stock option to purchase 50,000 shares of common stock to one new employee.

PDI, a global leader in infection prevention product and service solutions, today announced the appointment of Keyne Monson as Chief Commercial Officer (CCO).

Neurotrope, Inc. (Nasdaq: NTRP) and Metuchen Pharmaceuticals, L.L.C., a privately held biopharmaceutical company focused on innovative therapeutics for men’s health conditions (“Metuchen”), today announced the completion of their previously announced merger following the satisfaction of all closing conditions required by the amended merger agreement (the “Merger Agreement”).

Proprio announced that spinal industry veteran Tommy Carls has joined as an advisor to the company.